• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

程序性死亡配体1（PD-L1）与恶性胸膜间皮瘤患者的预后：一项荟萃分析和生物信息学研究

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study.

作者信息

Jin Liu, Gu Weiling, Li Xueqin, Xie Liang, Wang Linhong, Chen Zhongwen

机构信息

Department of Control and Prevention of Chronic Non-communicable Diseases, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang, China.

Office, Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang,China.

出版信息

Ther Adv Med Oncol. 2020 Sep 29;12:1758835920962362. doi: 10.1177/1758835920962362. eCollection 2020.

DOI:10.1177/1758835920962362
PMID:33062064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7533928/
Abstract

BACKGROUND

The prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with malignant pleural mesothelioma (MPM) has been controversial according to previous investigations. Therefore, we conducted a meta-analysis to assess the potential prognostic significance of PD-L1 expression in MPM.

METHODS

PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were thoroughly searched for relevant original articles published before 9 April 2020. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS) and progression-free survival (PFS) were calculated. The results of the meta-analysis were verified using The Cancer Genome Atlas (TCGA) dataset.

RESULTS

In total 16 studies were included in our meta-analysis. A high PD-L1 expression was associated with a poor OS (HR = 1.53, 95% CI = 1.28-1.83,  < 0.001), but not a grave PFS (HR = 1.07, 95% CI = 0.82-1.39,  = 0.643) in MPM. Furthermore, the PD-L1 expression correlated with the sarcomatoid + biphasic type of MPM (odds ratio = 4.32, 95% CI = 2.16-8.64,  < 0.001). TCGA data indicated that PD-L1 was a significant prognostic factor for OS (HR = 2.069, 95% CI = 1.136-3.769,  = 0.0175), but not for PFS (HR = 1.205, 95% CI = 0.572-2.539,  = 0.624), which was in accordance with the results of the meta-analysis.

CONCLUSION

A high PD-L1 expression is a significant prognostic factor for poor OS of patients with MPM. We therefore suggest that PD-L1 expression levels can be used to predict the clinical outcomes of patients with MPM in the future.

摘要

背景

根据以往的研究，程序性死亡配体1（PD-L1）表达在恶性胸膜间皮瘤（MPM）患者中的预后价值一直存在争议。因此，我们进行了一项荟萃分析，以评估PD-L1表达在MPM中的潜在预后意义。

方法

全面检索了PubMed、Embase、Web of Science、Scopus和Cochrane图书馆，查找2020年4月9日前发表的相关原始文章。计算总生存期（OS）和无进展生存期（PFS）的合并风险比（HR）和95%置信区间（CI）。使用癌症基因组图谱（TCGA）数据集验证荟萃分析的结果。

结果

我们的荟萃分析共纳入16项研究。在MPM中，高PD-L1表达与较差的OS相关（HR = 1.53，95%CI = 1.28 - 1.83，P < 0.001），但与严重的PFS无关（HR = 1.07，95%CI = 0.82 - 1.39，P = 0.643）。此外，PD-L1表达与MPM的肉瘤样+双相型相关（优势比 = 4.32，95%CI = 2.16 - 8.64，P < 0.001）。TCGA数据表明，PD-L1是OS的一个显著预后因素（HR = 2.069，95%CI = 1.136 - 3.769，P = 0.0175），但不是PFS的预后因素（HR = 1.205，95%CI = 0.572 - 2.539，P = 0.624），这与荟萃分析的结果一致。

结论

高PD-L1表达是MPM患者OS较差的一个显著预后因素。因此，我们建议未来可将PD-L1表达水平用于预测MPM患者的临床结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/c31af9231faf/10.1177_1758835920962362-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/176256100539/10.1177_1758835920962362-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/45e021580553/10.1177_1758835920962362-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/edac66434d13/10.1177_1758835920962362-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/ddcf51b71fb9/10.1177_1758835920962362-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/b2e67cc13187/10.1177_1758835920962362-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/c31af9231faf/10.1177_1758835920962362-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/176256100539/10.1177_1758835920962362-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/45e021580553/10.1177_1758835920962362-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/edac66434d13/10.1177_1758835920962362-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/ddcf51b71fb9/10.1177_1758835920962362-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/b2e67cc13187/10.1177_1758835920962362-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f50d/7533928/c31af9231faf/10.1177_1758835920962362-fig6.jpg

相似文献

1
PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study.程序性死亡配体1（PD-L1）与恶性胸膜间皮瘤患者的预后：一项荟萃分析和生物信息学研究
Ther Adv Med Oncol. 2020 Sep 29;12:1758835920962362. doi: 10.1177/1758835920962362. eCollection 2020.
2
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.恶性胸膜间皮瘤患者中 PD-L1 高表达与肉瘤样或双相组织学亚型相关的生存期更短：来自 Bio-MAPS 队列的 214 例系列病例。
Clin Lung Cancer. 2019 Sep;20(5):e564-e575. doi: 10.1016/j.cllc.2019.04.010. Epub 2019 May 13.
3
Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.程序性死亡配体 1 在恶性胸膜间皮瘤中的预后和临床病理效用：荟萃分析。
Int Immunopharmacol. 2020 Jun;83:106481. doi: 10.1016/j.intimp.2020.106481. Epub 2020 Apr 24.
4
Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.程序性死亡配体 1（PD-L1）在卵巢癌中的预后作用：系统评价、荟萃分析和生物信息学研究。
J Ovarian Res. 2019 Apr 30;12(1):37. doi: 10.1186/s13048-019-0512-6.
5
Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.循环肿瘤细胞中程序性死亡配体 1 表达对多种癌症的预后意义：系统评价和荟萃分析。
Cancer Med. 2021 Oct;10(20):7021-7039. doi: 10.1002/cam4.4236. Epub 2021 Aug 23.
6
PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma.程序性死亡配体1（PD-L1）表达补充了CALGB预后评分系统在恶性胸膜间皮瘤中的作用。
Front Oncol. 2023 Dec 4;13:1269029. doi: 10.3389/fonc.2023.1269029. eCollection 2023.
7
The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.肾细胞癌患者中PD-L1和PD-L2的患病率、预后及临床病理价值：一项纳入3389例患者的系统评价和荟萃分析
Transl Androl Urol. 2020 Apr;9(2):367-381. doi: 10.21037/tau.2020.01.21.
8
Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma.PD-L1 在可切除性胸膜间皮瘤中的预后作用。
Ann Thorac Surg. 2021 Nov;112(5):1575-1583. doi: 10.1016/j.athoracsur.2020.10.031. Epub 2020 Nov 27.
9
Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.程序性死亡受体 1 配体（PD-L1）表达升高预示着宫颈癌患者的生存结局较差。
Cancer Cell Int. 2019 May 23;19:146. doi: 10.1186/s12935-019-0861-7. eCollection 2019.
10
Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.实体瘤中PD-L1的预后意义：一项更新的荟萃分析。
Medicine (Baltimore). 2017 May;96(18):e6369. doi: 10.1097/MD.0000000000006369.

引用本文的文献

1
Consensus Guideline for the Management of Peritoneal Mesothelioma.腹膜间皮瘤管理共识指南
Ann Surg Oncol. 2025 Jun 25. doi: 10.1245/s10434-025-17358-x.
2
Immunotherapy for advanced and recurrent malignant pleural mesothelioma.恶性胸膜间皮瘤的晚期和复发性免疫治疗。
Cochrane Database Syst Rev. 2024 Sep 18;9(9):CD014720. doi: 10.1002/14651858.CD014720.
3
PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma.程序性死亡配体1（PD-L1）表达补充了CALGB预后评分系统在恶性胸膜间皮瘤中的作用。

本文引用的文献

1
A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients.PD-L1在黑色素瘤中预后价值的汇总分析：来自1062例患者的证据
Cancer Cell Int. 2020 Mar 30;20:96. doi: 10.1186/s12935-020-01187-x. eCollection 2020.
2
Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.程序性细胞死亡配体 1（PD-L1）在肝细胞癌中的预后价值：一项荟萃分析。
Biosci Rep. 2020 Apr 30;40(4). doi: 10.1042/BSR20200459.
3
Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy.
Front Oncol. 2023 Dec 4;13:1269029. doi: 10.3389/fonc.2023.1269029. eCollection 2023.
4
Small and Large Extracellular Vesicles Derived from Pleural Mesothelioma Cell Lines Offer Biomarker Potential.源自胸膜间皮瘤细胞系的小细胞外囊泡和大细胞外囊泡具有生物标志物潜力。
Cancers (Basel). 2023 Apr 18;15(8):2364. doi: 10.3390/cancers15082364.
5
Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.肾盂肉瘤样尿路上皮癌行免疫治疗。
BMC Urol. 2023 Mar 18;23(1):38. doi: 10.1186/s12894-023-01210-z.
6
The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.恶性胸膜间皮瘤中基因-干性-分泌组的相互作用：分子动力学与临床提示
Int J Mol Sci. 2023 Feb 9;24(4):3496. doi: 10.3390/ijms24043496.
7
Immunotherapy approaches for malignant pleural mesothelioma.恶性胸膜间皮瘤的免疫治疗方法。
Nat Rev Clin Oncol. 2022 Sep;19(9):573-584. doi: 10.1038/s41571-022-00649-7. Epub 2022 Jul 1.
8
The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review.程序性死亡配体1在恶性胸膜间皮瘤中的预测和预后性质：一项系统文献综述
JTO Clin Res Rep. 2022 Mar 22;3(5):100315. doi: 10.1016/j.jtocrr.2022.100315. eCollection 2022 May.
9
Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis.程序性细胞死亡配体1在未经术前治疗的食管鳞状细胞癌患者中的预后作用：一项系统评价和荟萃分析
Front Oncol. 2021 Aug 18;11:693886. doi: 10.3389/fonc.2021.693886. eCollection 2021.
10
IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells.白细胞介素-27介导人间皮瘤细胞程序性死亡配体-1的表达与释放。
Cancers (Basel). 2021 Aug 9;13(16):4011. doi: 10.3390/cancers13164011.
程序性细胞死亡配体 1：癌症治疗中的动态免疫检查点。
Chem Biol Drug Des. 2020 Jun;95(6):552-566. doi: 10.1111/cbdd.13677. Epub 2020 Mar 28.
4
The Prognostic Role of Programmed Death-Ligand 1 in Nasopharyngeal Carcinoma.程序性死亡配体 1 在鼻咽癌中的预后作用。
Laryngoscope. 2020 Nov;130(11):2598-2606. doi: 10.1002/lary.28523. Epub 2020 Feb 29.
5
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.不可切除恶性胸膜间皮瘤中免疫检查点抑制剂的现有证据和未来展望。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000461.
6
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.恶性胸膜间皮瘤：当前治疗方法的最新进展及未来展望
Front Oncol. 2020 Jan 24;9:1519. doi: 10.3389/fonc.2019.01519. eCollection 2019.
7
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.NIBIT-MESO-1研究中恶性间皮瘤患者循环中PD-L1水平：与生存的相关性
Cancers (Basel). 2020 Feb 5;12(2):361. doi: 10.3390/cancers12020361.
8
Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.非霍奇金淋巴瘤中PD-L1过表达的预后价值及临床病理特征：一项荟萃分析
BMC Cancer. 2020 Jan 28;20(1):59. doi: 10.1186/s12885-020-6550-z.
9
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.分析一系列恶性胸膜间皮瘤（MPM）患者错配修复（MMR）蛋白的表达。
Clin Transl Oncol. 2020 Aug;22(8):1390-1398. doi: 10.1007/s12094-019-02275-9. Epub 2020 Jan 8.
10
Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.间皮瘤分割放疗和手术治疗后肿瘤微环境的预后影响。
J Thorac Cardiovasc Surg. 2020 May;159(5):2082-2091.e1. doi: 10.1016/j.jtcvs.2019.10.122. Epub 2019 Nov 13.